Aptevo Therapeutics Inc. — Form 8-K Summary
Reporting date: September 22, 2026; filed and signed September 23, 2026. The filing reports voting results from the company’s Special Meeting of Stockholders. A quorum was present.
Business Context and Financial Information
The filing concerns corporate governance, equity issuance, and equity compensation matters. It does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating financial metrics.
Special Meeting Voting Results
| Proposal | Result | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|---|
| Amended and Restated Certificate of Incorporation technical and administrative amendments | Not approved | 654,005 | 93,851 | 4,759 | 0 |
| Issuance of more than 20% of outstanding common stock under warrant reload and private placement transactions | Approved | 319,306 | 100,098 | 4,225 | 328,986 |
| Fifth Amended and Restated 2018 Stock Incentive Plan | Approved | 331,590 | 82,399 | 9,640 | 328,986 |
| Authorization to adjourn the Special Meeting if necessary or appropriate | Approved | 639,823 | 92,829 | 19,963 | 0 |
Material Changes and Outlook
- Stockholders approved the proposed issuance of more than 20% of the company’s common stock as of August 12, 2026, pursuant to warrant reload and private placement transactions with certain holders, in accordance with Nasdaq Listing Rule 5635(d).
- Stockholders approved the Fifth Amended and Restated 2018 Stock Incentive Plan.
- The proposed technical and administrative amendments to the certificate of incorporation were not approved.
- The filing contains no management guidance, operating outlook, liquidity forecast, risk update, contingency disclosure, or unusual financial item.
Important Facts to Verify
- Review the August 31, 2026 definitive proxy statement for the terms, size, pricing, dilution impact, and use of proceeds associated with the warrant reload and private placement transactions.
- Confirm the number of shares and awards authorized under the Fifth Amended and Restated 2018 Stock Incentive Plan.
- Assess the potential ownership dilution from the approved issuance, including shares issuable upon warrant exercise.
- Confirm whether the failed certificate amendments affect any planned corporate actions or transaction documentation.
- Review subsequent SEC filings for closing details, share issuances, warrant terms, and updated capitalization.